ODYSSEY THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 10Avg age 55Avg tenure 3.3y
GG
Gary Glick
Chief Executive Officer
Age 64Since 2021-03-31Profile →
+14
Executives5
Board of directors10
GG
Gary Glick→
Director/Board Member
Age 64Since 2021-03-31
VO
Valerie Odegard→
Director/Board Member
Age 48Since 2021-09-30
JL
Jeffrey Leiden→
Chairman
Age 70Since 2022-02-28
IS
Ian Smith→
Director/Board Member
Age 60Since 2024-07-31
TW
Timothy Walbert→
Director/Board Member
Age 59Since 2024-05-31
SC
Shelley Chu→
Director/Board Member
Age 56Since 2025-07-31
PH
Paulina Hill→
Director/Board Member
Age 44Since 2025-05-31
NL
Nan Li→
Director/Board Member
Age 40Since 2025-05-31
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Fidelity Management & Research Co. LLC | 9.703 % | 4,577,262 |
| SR One Capital Management LP | 8.044 % | 3,794,883 |
| TPG Group Holdings (SBS) Advisors, Inc. | 7.822 % | 3,690,146 |
| Jeito Capital SASU | 7.822 % | 3,690,145 |
| Lightspeed Management Co LLC | 7.649 % | 3,608,443 |
Catalog · 2026-07-09
Registry officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Anthony Opipari | Chief Tech/Sci/R&D Officer | 2021-03-31 | - |
| Gary Glick | Chief Executive Officer | 2021-03-31 | - |
| Jason Haas | Director of Finance/CFO | 2024-11-30 | - |
| Jeffrey Leiden | Chairman | 2022-02-28 | - |
| Natalie Dales | Chief Tech/Sci/R&D Officer | 2022-10-31 | - |
| Carolyn Ng | Director/Board Member | 2015-06-30 | - |
| Gary Glick | Director/Board Member | 2021-03-31 | - |
| Ian Smith | Director/Board Member | 2024-07-31 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 35.33Range 27–44Analysts 6
27Mean 35.3344
- Strong buy 2
- Buy 6
Broker actions10
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| UBS | Initiated | Buy | 27 | 2026-10-12 |
| Raymond James | Initiated | Outperform | 42 | 2026-10-09 |
| HC Wainwright & Co. | Initiated | Buy | 44 | 2026-08-27 |
| JP Morgan | Maintained | Overweight | 29 | 2026-08-07 |
| Oppenheimer | Reiterated | Outperform | 40 | 2026-06-18 |
| Cantor Fitzgerald | Initiated | Overweight | — | 2026-06-02 |
| TD Cowen | Initiated | Buy | — | 2026-06-02 |
| Wedbush | Initiated | Outperform | 30 | 2026-06-02 |
| JP Morgan | Initiated | Overweight | 26 | 2026-06-02 |
| Oppenheimer | Initiated | Outperform | 40 | 2026-06-02 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.